#United States #New York #Levi & Korsinsky #Oculis Holding AG #OCS-01 DME

Oculis Holding AG Under Investigation After Major Stock Decline

In a shocking turn of events, Oculis Holding AG, a company listed on NASDAQ under the ticker symbol OCS, has seen its stock price plummet by approximately 23.4% in a single trading session. This sudden drop followed the company's announcement that their Phase 3 DIAMOND trials for their lead product, OCS-01, had failed to meet the primary endpoint for treating diabetic macular edema (DME). Furthermore, the company disclosed that it would not seek FDA approval for this indication, leading to substantial losses for shareholders.

Prior to this devastating revelation, Oculis had assured investors via multiple SEC filings that the OCS-01 DME program was making steady progress towards regulatory approval. A prospectus supplement filed on October 31, 2025, projected positive topline results from the DIAMOND trials and indicated that a new drug application would be submitted to the U.S. FDA in the fourth quarter of 2026. Similarly, a filing dated October 6, 2025, portrayed Oculis as well-positioned with several pivotal studies targeting lucrative markets. These optimistic portrayals sharply contrasted with the reality shared by the company on their latest announcement.

In light of these events, Levi & Korsinsky, LLP, a law firm specializing in shareholder rights, has initiated an investigation into potential securities law violations by Oculis Holding AG. The firm seeks to determine if Oculis misled investors by making false or misleading claims about the status and viability of their OCS-01 DME program. Investors who have lost money due to this situation are encouraged to participate in the investigation.

Impact on Investors

For those who invested in Oculis shares and experienced losses, this development marks a significant concern. The feedback from investors suggests a sense of betrayal, as many feel they had received a false sense of security from the company's previous statements. In the aftermath of the trial failures and stock drop, Oculis stockholders are being encouraged to gather relevant financial records to assess their options moving forward. Consulting with legal professionals about potential claims is also recommended.

Levi & Korsinsky’s Role

Levi & Korsinsky has a strong reputation in the field, having been ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years. Their investigation will focus on several key aspects, including material statements made in the company's prospectus supplements, 6-K filings, and other disclosures that could be deemed misleading. Investors have been assured that there is no upfront cost to participate in the investigation, as actions taken on behalf of the investors will operate on a contingency basis.

FAQs about the OCS Investigation

• - Who is conducting the investigation? Levi & Korsinsky is spearheading the investigation in response to potential securities law violations.
• - What statements are under scrutiny? The firm will examine any misleading claims made by Oculis about the OCS-01 DME program’s regulatory path.
• - How much has OCS stock dropped? The stock saw a decline of over 23% after the announcement regarding the Phase 3 trial failures.
• - What should investors do now? Gather documentation of purchases and contact Levi & Korsinsky for a complimentary evaluation.
• - Is there a cost to participate? There are no fees; participating in the investigation is at no cost to investors.

Conclusion

The downfall of Oculis Holding AG serves as a stark reminder of the volatility present in the pharmaceutical sector and the critical importance of transparency and disclosure from companies. With investigations now in motion, affected shareholders may have a path to seek restitution for their losses. As the legal proceedings unfold, many will be watching closely for how this situation impacts the future of Oculis and its commitment to its investors.